Clive Holmes
A5064532444- Alzheimer's disease research and treatments
- Dementia and Cognitive Impairment Research
- Neuroinflammation and Neurodegeneration Mechanisms
- Tryptophan and brain disorders
- Genetic Associations and Epidemiology
- Bioinformatics and Genomic Networks
- Neurological Disease Mechanisms and Treatments
- Health Systems, Economic Evaluations, Quality of Life
- Cholinesterase and Neurodegenerative Diseases
- Geology and Paleoclimatology Research
- Computational Drug Discovery Methods
- Genomics and Rare Diseases
- Schizophrenia research and treatment
- Geological formations and processes
- Folate and B Vitamins Research
- Neurological Disorders and Treatments
- Rheumatoid Arthritis Research and Therapies
- Nutrition, Genetics, and Disease
- Medicinal Plant Extracts Effects
- Parkinson's Disease Mechanisms and Treatments
- Stress Responses and Cortisol
- Treatment of Major Depression
- Diet and metabolism studies
- Pharmaceutical Practices and Patient Outcomes
- Intensive Care Unit Cognitive Disorders
University of Southampton
2015-2024
Moorgreen Hospital
2014-2024
Southern Health NHS Foundation Trust
2013-2024
Health Foundation
2013-2024
Oxford University Hospitals NHS Trust
2024
Genomics (United Kingdom)
2020
University of Pennsylvania
2017-2020
Keele University
2019
Southampton General Hospital
2005-2019
The University of Texas Health Science Center at San Antonio
2018
Clinical trials have shown the benefits of cholinesterase inhibitors for treatment mild-to-moderate Alzheimer's disease. It is not known whether continue after progression to moderate-to-severe
Objective: To prospectively validate the Montreal Cognitive Assessment (MoCA) in a UK memory clinic. Method: We administered MoCA and Mini-Mental State Examination (MMSE) to 32 subjects fulfilling diagnostic criteria for dementia, 23 mild cognitive impairment (MCI), 12 clinic comparison subjects, at baseline then 6-month follow-up. Clinical diagnoses dementia MCI were made according ICD-10 Petersen criteria. The sensitivity specificity of both measures assessed detection dementia. Results:...
Background Late Onset Alzheimer's disease (LOAD) is the leading cause of dementia. Recent large genome-wide association studies (GWAS) identified first strongly supported LOAD susceptibility genes since discovery involvement APOE in early 1990s. We have now exploited these GWAS datasets to uncover key pathophysiological processes. Methodology applied a recently developed tool for mining data biologically meaningful information dataset. The principal findings were then tested an independent...
The identification of subjects at high risk for Alzheimer's disease is important prognosis and early intervention. We investigated the polygenic architecture accuracy prediction models, including excluding component in model. This study used genotype data from powerful dataset comprising 17 008 cases 37 154 controls obtained International Genomics Project (IGAP). Polygenic score analysis tested whether alleles identified to associate with one sample set were significantly enriched relative...
Periodontitis is common in the elderly and may become more Alzheimer's disease because of a reduced ability to take care oral hygiene as progresses. Elevated antibodies periodontal bacteria are associated with an increased systemic pro-inflammatory state. Elsewhere raised serum cytokines have been rate cognitive decline disease. We hypothesized that periodontitis would be dementia severity rapid aimed determine if both decline, pro inflammatory In six month observational cohort study 60...
Agitation is a common and distressing symptom in patients with Alzheimer's disease. Cholinesterase inhibitors improve cognitive outcomes such patients, but the benefits of these drugs for behavioral disturbances are unclear.
A major feature of Alzheimer's disease is the accumulation amyloid-β peptide (Aβ) in brain both form plaques cerebral cortex and blood vessel as amyloid angiopathy (CAA). Experimental models human clinical trials have shown that Aβ can be reversed by immunotherapy. In this study, we hypothesized solubilized antibodies generated immunization drains via perivascular pathway, detectable an increase cerebrovascular Aβ. We performed a follow up study patients immunized against Aβ42....
In vivo imaging of brain β-amyloid, a hallmark Alzheimer disease, may assist in the clinical assessment suspected disease. To determine sensitivity and specificity positron emission tomography with flutemetamol injection labeled radioactive fluorine 18 to detect β-amyloid using neuropathologically determined neuritic plaque levels as standard truth. Open-label multicenter study that took place at dementia clinics, memory centers, hospice centers United States England from June 22, 2010,...